Designing drugs against heterogeneous targets
- 1 January 2002
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 20 (1), 15-16
- https://doi.org/10.1038/nbt0102-15
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The Binding Energetics of First- and Second-Generation HIV-1 Protease Inhibitors: Implications for Drug DesignArchives of Biochemistry and Biophysics, 2001
- Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypesProceedings of the National Academy of Sciences, 2001
- Thermodynamic Basis of Resistance to HIV-1 Protease Inhibition: Calorimetric Analysis of the V82F/I84V Active Site Resistant MutantBiochemistry, 2000
- Antiretroviral Drug Resistance Testing in Adult HIV-1 InfectionJAMA, 2000
- GenBankNucleic Acids Research, 1998
- Molecular Basis of HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Proteases Complexed with Cyclic Urea InhibitorsBiochemistry, 1997
- Crystal Structures of Complexes of a Peptidic Inhibitor with Wild-Type and Two Mutant HIV-1 Proteases,Biochemistry, 1996
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.Proceedings of the National Academy of Sciences, 1994